

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

PROFIT WARNING

This announcement is made by Sinco Pharmaceuticals Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders and potential investors of the Company that, based on a preliminary assessment of the unaudited management accounts of the Group for the six months ended 30 June 2016 (the “**Reporting Period**”), the Group expects to record a significant decline in profit for the Reporting Period as compared with that for the corresponding period in 2015. This is mainly attributable to (i) the non-recurring expenses recognized during the Reporting Period of approximately RMB17.5 million in connection with the listing of the shares of the Company on the main board of the Stock Exchange (the “**Listing**”); and (ii) an increase in intermediary professional service fees incurred after the Listing in the amount of approximately RMB2.1 million.

Without taking into account the impact of the aforesaid expenses, the Group is expected to make a profit in line with that for the corresponding period in 2015.

The Company is in the process of finalising the results of the Group for the Reporting Period. The information contained in this announcement is only a preliminary assessment by the Board with reference to the latest information currently available which has not been audited nor reviewed by the Company’s auditor and may be subject to change. The actual results for the Reporting Period may be different from what is disclosed in this announcement. Shareholders and potential investors of the Company are advised to read the announcement of the results for the Reporting Period carefully, which is expected to be announced in August 2016.

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

By Order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Hong Kong, 29 July 2016

As at the date of this announcement, the executive directors of the Company are Mr. Huang Xiangbin and Ms. Zhang Zhijie, and the independent non-executive directors of the Company are Mr. Chow Siu Lui, Mr. Wang Qing and Mr. Liu Wenfang.